Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Jan;20(1):39-44.
doi: 10.1097/PAP.0b013e31827b665b.

A model for the design and construction of a resource for the validation of prognostic prostate cancer biomarkers: the Canary Prostate Cancer Tissue Microarray

Sarah Hawley  1 , Ladan Fazli, Jesse K McKenney, Jeff Simko, Dean Troyer, Marlo Nicolas, Lisa F Newcomb, Janet E Cowan, Luis Crouch, Michelle Ferrari, Javier Hernandez, Antonio Hurtado-Coll, Kyle Kuchinsky, Janet Liew, Rosario Mendez-Meza, Elizabeth Smith, Imelda Tenggara, Xiaotun Zhang, Peter R Carroll, June M Chan, Martin Gleave, Raymond Lance, Daniel W Lin, Peter S Nelson, Ian M Thompson, Ziding Feng, Lawrence D True, James D Brooks
Affiliations
Review

A model for the design and construction of a resource for the validation of prognostic prostate cancer biomarkers: the Canary Prostate Cancer Tissue Microarray

Sarah Hawley et al. Adv Anat Pathol. 2013 Jan.

Abstract

Tissue microarrays (TMAs) provide unique resources for rapid evaluation and validation of tissue biomarkers. The Canary Foundation Retrospective Prostate Tissue Microarray Resource used a rigorous statistical design, quota sampling, a variation of the case-cohort study, to select patients for inclusion in a multicenter, retrospective prostate cancer TMA cohort. The study is designed to definitively validate tissue biomarkers of prostate cancer recurrence after radical prostatectomy. Tissue samples from over 1000 participants treated for prostate cancer with radical prostatectomy between 1995 and 2004 were selected at 6 participating institutions in the United States and Canada. This design captured the heterogeneity of screening and clinical practices in the contemporary North American population. Standardized clinical data were collected in a centralized database. The project has been informative in several respects. The scale and complexity of assembling TMAs with over 200 cases at each of 6 sites involved unanticipated levels of effort and time. Our statistical design promises to provide a model for outcome-based studies where tissue localization methods are applied to high-density TMAs.

PubMed Disclaimer

References

    1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 60:277–300. - PubMed
    1. Roehl KA, Han M, Ramos CG, Antenor JA, Catalona WJ. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol. 2004;172:910–914. - PubMed
    1. Raldow A, Hamstra DA, Kim SN, Yu JB. Adjuvant radiotherapy after radical prostatectomy: evidence and analysis. Cancer Treat Rev. 37:89–96. - PubMed
    1. Han M, Partin AW, Pound CR, Epstein JI, Walsh PC. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am. 2001;28:555–565. - PubMed
    1. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360:1320–1328. - PubMed

Publication types

Substances